Everything below concerns Peptidase stability. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-24. Numbers and descriptions here follow the published literature rather than marketing material.
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.
Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.
Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.
Enzymatic stability motivates the extra three residues at the carboxyl end. Native tuftsin is cleaved quickly by circulating aminopeptidases and carboxypeptidases, which limits its duration of action and its usefulness as a tool compound. Extending the chain with proline-rich segments is a common design tactic because proline constrains the backbone and slows proteolysis. The same Pro-Gly-Pro motif appears in other Russian-developed peptides of the era. Whether the full seven-residue chain is required for activity, or whether it acts mainly as a prodrug releasing tuftsin, remains unresolved.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Modeled on tuftsin |
| Amino acid sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Seven residues |
| Approximate molecular mass | Around 750 Da | Depends on counter-ion and hydration |
| Common forms | Lyophilized powder | Also described as aqueous solution |
| Primary origin of research | Russian laboratories | Mid-1990s onward |
Characterization of Selank in laboratory settings relies on standard peptide analytical techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and degradation products, while mass spectrometry confirms molecular identity through accurate mass measurement. Amino acid analysis and peptide sequencing verify the primary structure when reference material is unavailable. Because Selank is a short chain, fragmentation-based analysis produces a diagnostic ion pattern that supports confident identification.
Peptide stability depends strongly on temperature, moisture, and pH. Lyophilized Selank is generally most stable when stored cold and dry, with freezer temperatures commonly used for long-term storage. In solution, the compound is susceptible to hydrolysis and to microbial growth if it is not handled aseptically. The C-terminal proline-rich extension appears to slow enzymatic cleavage relative to tuftsin, though quantitative degradation rates vary with the matrix and the conditions tested. Published stability data specific to Selank remain sparse.
Quality assessment of Selank samples typically combines purity determination with identity confirmation and counter-ion analysis. Purity is usually reported as a percentage by chromatographic area, with values above 95 percent often quoted for research-grade material. Water content and residual solvents are checked in lyophilized batches because they affect both stability and accurate mass determination. A reported purity figure does not by itself establish that a sample is the intended sequence, so orthogonal methods are needed to rule out sequence isomers or truncation products.
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.
Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.
=== Nonsense mutations === Nearly 11% of all inherited genetic disorders are caused by premature stop codon (nonsense mutations). Notable examples of nonsense mutations that have received extensive research are the CFTR, which causes cystic fibrosis, and dystrophin mutations, which causes Duchenne muscular dystrophy. Recent therapeutic research has focused on forcing readthrough of premature stop codons. This would allow the previously mutated mRNA strand to potentially code for a correctly folded protein. A common method of forcing readthrough is to limit the activity of eRF1 and eRF3. One mechanism proposed limiting the concentrations of eRF1 and eRF3 in the cells, which would theoretically reduce stop codon recognition. However, this mechanism has not been used in therapeutic remedies. Instead the most promising mechanism involves chemical degradation of eRF1 to achieve readthrough. These chemicals are under the branch of drugs called readthrough promoters. The mechanism of readthrough promoters vary, however a common mechanism is to prevent eRF1 from releasing out of the ribosome. This results in a stalled ribosome then finally a collision with another ribosome.
AAS performs this analysis by subjecting the sample to an extremely high heat source, breaking the atomic bonds of the substance, leaving free atoms. Radiation in the form of light is then passed through the sample forcing the atoms to jump to a higher energy state. Forensic chemists can test for each element by using a corresponding wavelength of light that forces that element's atoms to a higher energy state during the analysis. For this reason, and due to the destructive nature of this method, AAS is generally used as a confirmatory technique after preliminary tests have indicated the presence of a specific element in the sample. The concentration of the element in the sample is proportional to the amount of light absorbed when compared to a blank sample. AAS is useful in cases of suspected heavy metal poisoning such as with arsenic, lead, mercury, and cadmium. The concentration of the substance in the sample can indicate whether heavy metals were the cause of death.
Recent biochemical analysis of the mummies has revealed that the victims had consumed increasing quantities of alcohol and coca, possibly in the form of chicha, in the months leading up to sacrifice. The dominant theory for the drugging reasons that, alongside ritual uses, the substances probably made the children more docile. Chewed coca leaves found inside the eldest child's mouth upon her discovery in 1999 supports this theory. The bodies of Inca emperors and wives were mummified after death. In 1533, the Spanish conquistadors of the Inca Empire viewed the mummies in the Inca capital of Cuzco. The mummies were displayed, often in lifelike positions, in the palaces of the deceased emperors and had a retinue of servants to care for them. The Spanish were impressed with the quality of the mummification which involved removal of the organs, embalming, and freeze-drying. The population revered the mummies of the Inca emperors. This reverence seemed idolatry to the Roman Catholic Spanish and in 1550 they confiscated the mummies. The mummies were taken to Lima where they were displayed in the San Andres Hospital. The mummies deteriorated in the humid climate of Lima and eventually they were either buried or destroyed by the Spanish. An attempt to find the mummies of the Inca emperors beneath the San Andres hospital in 2001 was unsuccessful. The archaeologists found a crypt, but it was empty. Possibly the mummies had been removed when the building was repaired after an earthquake.
As mayor, Newsom focused on development projects in Hunters Point and Treasure Island. He gained national attention in 2004 when he directed the San Francisco city–county clerk to issue marriage licenses to same-sex couples, violating a state law passed in 2000. Implementation of Care Not Cash, the initiative he had sponsored as a supervisor, began on July 1, 2004. As part of the initiative, 5,000 more homeless people were given permanent shelter in the city. About 2,000 people had been placed into permanent housing with support by 2007. Other programs Newsom initiated to end chronic homelessness included the San Francisco Homeless Outreach Team (SF HOT) and Project Homeless Connect (PHC), which placed 2,000 homeless people into permanent housing and provided 5,000 additional affordable rental units in the city. During a strike by hotel workers against a dozen San Francisco hotels, Newsom joined UNITE HERE union members on a picket line in front of the Westin St. Francis Hotel on October 27, 2004. He vowed that the city would boycott the hotels by not sponsoring city events at them until they agreed to a contract with workers; the contract dispute was settled in September 2006. In 2005, Newsom pushed for a state law to allow California communities to create policy restricting certain breeds of dogs. In 2007, he signed the law establishing Healthy San Francisco to provide city residents with universal health care, the first city in the nation to do so.
Sources: en.wikipedia.org
=== Viable analytes === Various compounds, including peptides, dinucleotides, prostaglandins, diquaternary ammonium salts, pesticides, drugs, dyes, and environmental pollutants can be analyzed using thermospray.
Major Charles Karu Singleton, The Princess of Wales's Royal Regiment, 565366. Staff Sergeant Charlotte Louise Spence, Royal Army Physical Training Corps, W1060016. Major Jonathan Grant Studwell, Intelligence Corps, 30170101. Major Thomas Daniel Sweeney, Army Air Corps, 24757307. Sergeant Edward William Swindell, , Corps of Royal Engineers, Army Reserve, 30150063. Major Francesca Louise Sykes, Royal Regiment of Artillery, 30067880. Lieutenant Colonel Andrew James Teeton, Corps of Royal Engineers, 536346. Major (now Acting Lieutenant Colonel) James Viney, Corps of Royal Engineers, 25185183. Captain (now Acting Major) David Edward Williams, Corps of Royal Electrical and Mechanical Engineers, 24929032. Master Aircrew Oliver Martin Dewey, Royal Air Force, 30060196. Sergeant (now Acting Flight Sergeant) George Joseph Downey, Royal Air Force, L8516771. Wing Commander Sam Haley, Royal Air Force, 30000089. Squadron Leader James Duncan Hemingfield, Royal Air Force, 8700294K. Sergeant Martin John Henderson, Royal Air Force, 30112261. Squadron Leader Sharon Ingle, Royal Air Force, 30091084. Flight Sergeant (now Acting Warrant Officer) Stewart Marcus Jackson, Royal Air Force, F8427999. Flight Sergeant Philip Kipling, Royal Air Force, D8411323. Squadron Leader Kevin Charles William March, Royal Air Force, 30035301. Squadron Leader Christopher Scott Middleton, Royal Air Force, 2642751S. Squadron Leader Mark Shipley, Royal Air Force, 30001963. Warrant Officer Garry John Stanton, Royal Air Force, K8421673.
== CLIA identification number == CLIA identification numbers are 10-digit alphanumeric unique identifiers issued by the CLIA data system to identify a CLIA laboratory. This is assigned at the time of initial entry of the CLIA application and included with the mailing of the remittance fee coupon.
Sources: en.wikipedia.org
Selank is a synthetic peptide made of seven amino acids. It is modeled on tuftsin, a natural tetrapeptide, with an added three-residue tail. It is not a small-molecule drug.
It originates from research in Russia, associated with the Institute of Molecular Genetics of the Russian Academy of Sciences. The first descriptions date to the mid-1990s. Most published studies come from Russian laboratories.
No, Selank itself does not occur naturally. Its backbone is based on tuftsin, which is produced in the body, but the seven-residue version is a synthetic construct. It is supplied as a manufactured peptide.
Selank is a seven-amino-acid peptide built from the tuftsin sequence plus a Pro-Gly-Pro tail. It is produced by chemical synthesis rather than extracted from a natural source. The free peptide is usually supplied as a lyophilised powder or in an aqueous formulation.